Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)
Updated HCV clinical guidelines placed direct acting agents (DAAs) as the preferable the first line regimens.The objective of the study was PE assessment of HCV therapy among G1 naïve patientsMethods: Analysis is based on data of randomized clinical trials and average price of HCV medicines from sta...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Journal Infectology
2016-02-01
|
| Series: | Журнал инфектологии |
| Subjects: | |
| Online Access: | https://journal.niidi.ru/jofin/article/view/450 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849241180046360576 |
|---|---|
| author | A. V. Rudakova D. A. Gusev A. N. Uskov Yu. V. Lobzin |
| author_facet | A. V. Rudakova D. A. Gusev A. N. Uskov Yu. V. Lobzin |
| author_sort | A. V. Rudakova |
| collection | DOAJ |
| description | Updated HCV clinical guidelines placed direct acting agents (DAAs) as the preferable the first line regimens.The objective of the study was PE assessment of HCV therapy among G1 naïve patientsMethods: Analysis is based on data of randomized clinical trials and average price of HCV medicines from state auctions placed in state procurement system in 2015.Results: PTV/OBV/DSV/r cost is 30,5% lower vs PegIFN/RBV/SMV. In comparison with PegIFN/RBV/BCV combination PTV/OBV/DSV/r is cost saving by 10,6% at patients without cirrhosis and 36,2% at patients with cirrhosis. DCV/ASV combination is chipper PTV/OBV/DSV/r and it would be used for G1 naïve patient (cost saving is 9,4-10,4%). DCV/ASV and PTV/OBV/DSV/r SVR12 costs are comparable and significantly lower than PegIFN-based regimen: PegIFN/RBV/SMV and PegIFN/RBV/BCV. 4 weeks stop rules due to therapy inefficiency for PegIFN/RBV/SMV regimen could cut cost by 12,6% и 28,0% among patients without and cirrhosis accordingly. By way PTV/OBV/DSV/r is the most cost effective versus PegIFN/RBV/SMV. PTV/OBV/DSV/r as the first line therapy for PegIFN experienced patients provides budget saving 118,2 thousand RUB or 12,2% of budget.Conclusion: Right now PTV/OBV/DSV/r regimen is the most cost effective the first line therapy for naïve patients. |
| format | Article |
| id | doaj-art-9e184d8cbdb743a9bc49c69e3e12fd5d |
| institution | Kabale University |
| issn | 2072-6732 |
| language | Russian |
| publishDate | 2016-02-01 |
| publisher | Journal Infectology |
| record_format | Article |
| series | Журнал инфектологии |
| spelling | doaj-art-9e184d8cbdb743a9bc49c69e3e12fd5d2025-08-20T04:00:15ZrusJournal InfectologyЖурнал инфектологии2072-67322016-02-0174959910.22625/2072-6732-2015-7-4-95-99450Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)A. V. Rudakova0D. A. Gusev1A. N. Uskov2Yu. V. Lobzin3Science Research Institute of Children`s Infections, Saint-Petersburg, RussiaCenter for AIDS and Other Infectious Diseases, Saint-Petersburg, RussiaScience Research Institute of Children`s Infections, Saint-Petersburg, RussiaScience Research Institute of Children`s Infections, Saint-Petersburg, RussiaUpdated HCV clinical guidelines placed direct acting agents (DAAs) as the preferable the first line regimens.The objective of the study was PE assessment of HCV therapy among G1 naïve patientsMethods: Analysis is based on data of randomized clinical trials and average price of HCV medicines from state auctions placed in state procurement system in 2015.Results: PTV/OBV/DSV/r cost is 30,5% lower vs PegIFN/RBV/SMV. In comparison with PegIFN/RBV/BCV combination PTV/OBV/DSV/r is cost saving by 10,6% at patients without cirrhosis and 36,2% at patients with cirrhosis. DCV/ASV combination is chipper PTV/OBV/DSV/r and it would be used for G1 naïve patient (cost saving is 9,4-10,4%). DCV/ASV and PTV/OBV/DSV/r SVR12 costs are comparable and significantly lower than PegIFN-based regimen: PegIFN/RBV/SMV and PegIFN/RBV/BCV. 4 weeks stop rules due to therapy inefficiency for PegIFN/RBV/SMV regimen could cut cost by 12,6% и 28,0% among patients without and cirrhosis accordingly. By way PTV/OBV/DSV/r is the most cost effective versus PegIFN/RBV/SMV. PTV/OBV/DSV/r as the first line therapy for PegIFN experienced patients provides budget saving 118,2 thousand RUB or 12,2% of budget.Conclusion: Right now PTV/OBV/DSV/r regimen is the most cost effective the first line therapy for naïve patients.https://journal.niidi.ru/jofin/article/view/450chronic hepatitis cgenotype 1naïve patientsdirect acting agentscost effectiveness |
| spellingShingle | A. V. Rudakova D. A. Gusev A. N. Uskov Yu. V. Lobzin Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1) Журнал инфектологии chronic hepatitis c genotype 1 naïve patients direct acting agents cost effectiveness |
| title | Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1) |
| title_full | Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1) |
| title_fullStr | Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1) |
| title_full_unstemmed | Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1) |
| title_short | Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1) |
| title_sort | cost effectiveness of antiviral therapy in chronic hepatitis c g1 |
| topic | chronic hepatitis c genotype 1 naïve patients direct acting agents cost effectiveness |
| url | https://journal.niidi.ru/jofin/article/view/450 |
| work_keys_str_mv | AT avrudakova costeffectivenessofantiviraltherapyinchronichepatitiscg1 AT dagusev costeffectivenessofantiviraltherapyinchronichepatitiscg1 AT anuskov costeffectivenessofantiviraltherapyinchronichepatitiscg1 AT yuvlobzin costeffectivenessofantiviraltherapyinchronichepatitiscg1 |